Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 38.7% in December
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 38.7% in December
Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 688,300 shares, a growth of 38.7% from the December 15th total of 496,400 shares. Based on an average daily volume of 95,600 shares, the days-to-cover ratio is presently 7.2 days. Currently, 3.9% of the company's shares are short sold.
AURA生物科学公司(纳斯达克:AURA-GET评级)是空头股数在12月份实现大幅增长的接受者。截至12月30日,空头股数共有68.83万股,比12月15日的49.64万股增长了38.7%。根据日均成交量95,600股计算,目前的天数与回补比率为7.2天。目前,该公司3.9%的股票被卖空。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, JMP Securities increased their price target on shares of Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a research report on Friday, November 11th.
另外,JMP证券在11月11日(星期五)的一份研究报告中将Aura Biosciences的股票目标价从26.00美元上调至30.00美元,并给予该公司“市场表现优于大盘”的评级。
Insiders Place Their Bets
内部人士下注
In related news, CFO Julie B. Feder sold 2,015 shares of the business's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $12.45, for a total transaction of $25,086.75. Following the completion of the sale, the chief financial officer now directly owns 24,235 shares of the company's stock, valued at $301,725.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director David Michael Johnson acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, December 1st. The stock was acquired at an average price of $12.37 per share, for a total transaction of $123,700.00. Following the completion of the acquisition, the director now owns 15,000 shares of the company's stock, valued at approximately $185,550. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Julie B. Feder sold 2,015 shares of the firm's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $12.45, for a total value of $25,086.75. Following the transaction, the chief financial officer now owns 24,235 shares in the company, valued at approximately $301,725.75. The disclosure for this sale can be found here. In the last three months, insiders bought 1,264,396 shares of company stock valued at $15,166,660 and sold 4,802 shares valued at $59,796. Company insiders own 5.00% of the company's stock.
在相关新闻中,CFO Julie B.Feder在10月31日星期一的一笔交易中出售了2,015股该公司的股票。这些股票以12.45美元的平均价格出售,总成交额为25086.75美元。出售完成后,首席财务官现在直接拥有24,235股公司股票,价值301,725.75美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在这个环节。相关新闻,董事David迈克尔·约翰逊在12月1日(星期四)的一笔交易中购买了10,000股该公司的股票。该股票是以每股12.37美元的平均价格收购的,总交易额为123,700.00美元。收购完成后,董事现在拥有15,000股该公司的股票,价值约185,550美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过此超链接。此外,首席财务官朱莉·B·费德在日期为10月31日(星期一)的交易中出售了2,015股该公司股票。这只股票的平均售价为12.45美元,总价值为25086.75美元。交易完成后,这位首席财务官现在拥有该公司24,235股,价值约为301,725.75美元。关于这次销售的披露可以找到这里。在过去的三个月里,内部人士买入了1,264,396股公司股票,价值15,166,660美元,出售了4,802股,价值59,796美元。公司内部人士持有该公司5.00%的股份。
Institutional Investors Weigh In On Aura Biosciences
机构投资者参与Aura Bioscions
Aura Biosciences Trading Down 3.6 %
AURA生物科学公司股价下跌3.6%
AURA traded down $0.38 during mid-day trading on Thursday, hitting $10.07. The stock had a trading volume of 1,355 shares, compared to its average volume of 106,229. The stock's fifty day simple moving average is $12.05 and its 200-day simple moving average is $13.63. Aura Biosciences has a 1-year low of $9.43 and a 1-year high of $24.83.
AURA周四午盘交易中下跌0.38美元,触及10.07美元。该股成交量为1,355股,而其平均成交量为106,229股。该股的50日简单移动均线为12.05美元,200日简单移动均线为13.63美元。Aura Biosciences的一年低点为9.43美元,一年高位为24.83美元。
Aura Biosciences (NASDAQ:AURA – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.01). Equities research analysts anticipate that Aura Biosciences will post -2.02 EPS for the current year.
奥拉生物科学(纳斯达克:AURA-GET评级)最近一次发布季度收益数据是在11月10日(星期四)。该公司公布了该季度每股收益(0.53美元),低于分析师普遍预期的(0.52美元)和(0.01美元)。股票研究分析师预计,奥拉生物科学公司本年度的每股收益将达到2.02欧元。
Aura Biosciences Company Profile
奥拉生物科学公司简介
(Get Rating)
(获取评级)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Aura Biosciences,Inc.是一家开发癌症治疗方法的生物技术公司。该公司开发病毒样药物结合物(VDC)技术平台,用于治疗眼科和泌尿外科肿瘤学中高度未得到满足的肿瘤。它开发了AU-011,一种治疗原发脉络膜黑色素瘤的VDC候选药物。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
- 免费获取StockNews.com关于AURA生物科学的研究报告(AURA)
- 爱彼迎的涨幅是否会像分析师预测的那样达到38%?
- 特斯拉汽车降价是否意味着特斯拉股票也会降价?
- 微软的裁员标志着其他科技公司的裁员?
- 快速购买Fastenal的原因不止一个
- 3只有吸引力的防御性股票,股息为3%
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《奥拉生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aura Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。